Allosteric MEK1/2 Inhibitor Refametinib (BAY 86-9766) in Combination with Sorafenib Exhibits Antitumor Activity in Preclinical Murine and Rat Models of Hepatocellular Carcinoma
OBJECTIVE: The objectives of the study were to evaluate the allosteric mitogen-activated protein kinase kinase (MEK) inhibitor BAY 86-9766 in monotherapy and in combination with sorafenib in orthotopic and subcutaneous hepatocellular carcinoma (HCC) models with different underlying etiologies in tw...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2013-10-01
|
Series: | Neoplasia: An International Journal for Oncology Research |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1476558613801066 |
id |
doaj-7b75d1b09ebc420588d3c375c24ac183 |
---|---|
record_format |
Article |
spelling |
doaj-7b75d1b09ebc420588d3c375c24ac1832020-11-25T00:59:07ZengElsevierNeoplasia: An International Journal for Oncology Research1476-55861522-80022013-10-0115101161117110.1593/neo.13812Allosteric MEK1/2 Inhibitor Refametinib (BAY 86-9766) in Combination with Sorafenib Exhibits Antitumor Activity in Preclinical Murine and Rat Models of Hepatocellular CarcinomaRoberta Schmieder0Florian Puehler1Roland Neuhaus2Maria Kissel3Alex A Adjei4Jeffrey N Miner5Dominik Mumberg6Karl Ziegelbauer7Arne Scholz8Global Drug Discovery, Bayer HealthCare, Berlin, GermanyGlobal Drug Discovery, Bayer HealthCare, Berlin, GermanyGlobal Drug Discovery, Bayer HealthCare, Berlin, GermanyGlobal Drug Discovery, Bayer HealthCare, Berlin, GermanyRoswell Park Cancer Institute, Buffalo, NYArdea Biosciences, Inc, San Diego, CAGlobal Drug Discovery, Bayer HealthCare, Berlin, GermanyGlobal Drug Discovery, Bayer HealthCare, Berlin, GermanyGlobal Drug Discovery, Bayer HealthCare, Berlin, Germany OBJECTIVE: The objectives of the study were to evaluate the allosteric mitogen-activated protein kinase kinase (MEK) inhibitor BAY 86-9766 in monotherapy and in combination with sorafenib in orthotopic and subcutaneous hepatocellular carcinoma (HCC) models with different underlying etiologies in two species. DESIGN: Antiproliferative potential of BAY 86-9766 and synergistic effects with sorafenib were studied in several HCC cell lines. Relevant pathway signaling was studied in MH3924a cells. For in vivo testing, the HCC cells were implanted subcutaneously or orthotopically. Survival and mode of action (MoA) were analyzed. RESULTS: BAY 86-9766 exhibited potent antiproliferative activity in HCC cell lines with half-maximal inhibitory concentration values ranging from 33 to 762 nM. BAY 86-9766 was strongly synergistic with sorafenib in suppressing tumor cell proliferation and inhibiting phosphorylation of the extracellular signal-regulated kinase (ERK). BAY 86-9766 prolonged survival in Hep3B xenografts, murine Hepa129 allografts, and MH3924A rat allografts. Additionally, tumor growth, ascites formation, and serum alpha-fetoprotein levels were reduced. Synergistic effects in combination with sorafenib were shown in Huh-7, Hep3B xenografts, and MH3924A allografts. On the signaling pathway level, the combination of BAY 86-9766 and sorafenib led to inhibition of the upregulatory feedback loop toward MEK phosphorylation observed after BAY 86-9766 monotreatment. With regard to the underlying MoA, inhibition of ERK phosphorylation, tumor cell proliferation, and microvessel density was observed in vivo. CONCLUSION: BAY 86-9766 shows potent single-agent antitumor activity and acts synergistically in combination with sorafenib in preclinical HCC models. These results support the ongoing clinical development of BAY 86-9766 and sorafenib in advanced HCC. http://www.sciencedirect.com/science/article/pii/S1476558613801066 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Roberta Schmieder Florian Puehler Roland Neuhaus Maria Kissel Alex A Adjei Jeffrey N Miner Dominik Mumberg Karl Ziegelbauer Arne Scholz |
spellingShingle |
Roberta Schmieder Florian Puehler Roland Neuhaus Maria Kissel Alex A Adjei Jeffrey N Miner Dominik Mumberg Karl Ziegelbauer Arne Scholz Allosteric MEK1/2 Inhibitor Refametinib (BAY 86-9766) in Combination with Sorafenib Exhibits Antitumor Activity in Preclinical Murine and Rat Models of Hepatocellular Carcinoma Neoplasia: An International Journal for Oncology Research |
author_facet |
Roberta Schmieder Florian Puehler Roland Neuhaus Maria Kissel Alex A Adjei Jeffrey N Miner Dominik Mumberg Karl Ziegelbauer Arne Scholz |
author_sort |
Roberta Schmieder |
title |
Allosteric MEK1/2 Inhibitor Refametinib (BAY 86-9766) in Combination with Sorafenib Exhibits Antitumor Activity in Preclinical Murine and Rat Models of Hepatocellular Carcinoma |
title_short |
Allosteric MEK1/2 Inhibitor Refametinib (BAY 86-9766) in Combination with Sorafenib Exhibits Antitumor Activity in Preclinical Murine and Rat Models of Hepatocellular Carcinoma |
title_full |
Allosteric MEK1/2 Inhibitor Refametinib (BAY 86-9766) in Combination with Sorafenib Exhibits Antitumor Activity in Preclinical Murine and Rat Models of Hepatocellular Carcinoma |
title_fullStr |
Allosteric MEK1/2 Inhibitor Refametinib (BAY 86-9766) in Combination with Sorafenib Exhibits Antitumor Activity in Preclinical Murine and Rat Models of Hepatocellular Carcinoma |
title_full_unstemmed |
Allosteric MEK1/2 Inhibitor Refametinib (BAY 86-9766) in Combination with Sorafenib Exhibits Antitumor Activity in Preclinical Murine and Rat Models of Hepatocellular Carcinoma |
title_sort |
allosteric mek1/2 inhibitor refametinib (bay 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma |
publisher |
Elsevier |
series |
Neoplasia: An International Journal for Oncology Research |
issn |
1476-5586 1522-8002 |
publishDate |
2013-10-01 |
description |
OBJECTIVE: The objectives of the study were to evaluate the allosteric mitogen-activated protein kinase kinase (MEK) inhibitor BAY 86-9766 in monotherapy and in combination with sorafenib in orthotopic and subcutaneous hepatocellular carcinoma (HCC) models with different underlying etiologies in two species. DESIGN: Antiproliferative potential of BAY 86-9766 and synergistic effects with sorafenib were studied in several HCC cell lines. Relevant pathway signaling was studied in MH3924a cells. For in vivo testing, the HCC cells were implanted subcutaneously or orthotopically. Survival and mode of action (MoA) were analyzed. RESULTS: BAY 86-9766 exhibited potent antiproliferative activity in HCC cell lines with half-maximal inhibitory concentration values ranging from 33 to 762 nM. BAY 86-9766 was strongly synergistic with sorafenib in suppressing tumor cell proliferation and inhibiting phosphorylation of the extracellular signal-regulated kinase (ERK). BAY 86-9766 prolonged survival in Hep3B xenografts, murine Hepa129 allografts, and MH3924A rat allografts. Additionally, tumor growth, ascites formation, and serum alpha-fetoprotein levels were reduced. Synergistic effects in combination with sorafenib were shown in Huh-7, Hep3B xenografts, and MH3924A allografts. On the signaling pathway level, the combination of BAY 86-9766 and sorafenib led to inhibition of the upregulatory feedback loop toward MEK phosphorylation observed after BAY 86-9766 monotreatment. With regard to the underlying MoA, inhibition of ERK phosphorylation, tumor cell proliferation, and microvessel density was observed in vivo. CONCLUSION: BAY 86-9766 shows potent single-agent antitumor activity and acts synergistically in combination with sorafenib in preclinical HCC models. These results support the ongoing clinical development of BAY 86-9766 and sorafenib in advanced HCC.
|
url |
http://www.sciencedirect.com/science/article/pii/S1476558613801066 |
work_keys_str_mv |
AT robertaschmieder allostericmek12inhibitorrefametinibbay869766incombinationwithsorafenibexhibitsantitumoractivityinpreclinicalmurineandratmodelsofhepatocellularcarcinoma AT florianpuehler allostericmek12inhibitorrefametinibbay869766incombinationwithsorafenibexhibitsantitumoractivityinpreclinicalmurineandratmodelsofhepatocellularcarcinoma AT rolandneuhaus allostericmek12inhibitorrefametinibbay869766incombinationwithsorafenibexhibitsantitumoractivityinpreclinicalmurineandratmodelsofhepatocellularcarcinoma AT mariakissel allostericmek12inhibitorrefametinibbay869766incombinationwithsorafenibexhibitsantitumoractivityinpreclinicalmurineandratmodelsofhepatocellularcarcinoma AT alexaadjei allostericmek12inhibitorrefametinibbay869766incombinationwithsorafenibexhibitsantitumoractivityinpreclinicalmurineandratmodelsofhepatocellularcarcinoma AT jeffreynminer allostericmek12inhibitorrefametinibbay869766incombinationwithsorafenibexhibitsantitumoractivityinpreclinicalmurineandratmodelsofhepatocellularcarcinoma AT dominikmumberg allostericmek12inhibitorrefametinibbay869766incombinationwithsorafenibexhibitsantitumoractivityinpreclinicalmurineandratmodelsofhepatocellularcarcinoma AT karlziegelbauer allostericmek12inhibitorrefametinibbay869766incombinationwithsorafenibexhibitsantitumoractivityinpreclinicalmurineandratmodelsofhepatocellularcarcinoma AT arnescholz allostericmek12inhibitorrefametinibbay869766incombinationwithsorafenibexhibitsantitumoractivityinpreclinicalmurineandratmodelsofhepatocellularcarcinoma |
_version_ |
1725218804679573504 |